We are building a company with a bold ambition to become a leader in cancer vaccines, making patients active participants in their own fight against cancer. Cancer is an evolving target that constantly adapts to escape the immune system and resist to treatment. Given this high unmet need, we developed a tech-platform generating new therapeutic vaccines against cancer, called STC for ‘Stimulated-Tumor-(ghost)-Cells’. STC mimics, in the laboratory, the relapse conditions of patients' tumor cells to educate their immune systems to be able to anticipate, target and destroy these tumor cells as soon as they appear. Our patented platform uses an in-depth understanding of the cancer’s complexity, validated by innovative proteomic analysis cross-matched with patient’s biopsies’ human databases to offer a new type of precision treatment with control on time and cost of manufacturing and supply.